Navigation Links
Selexis SA to Present and Partner at the BIO-Europe 2013 Partnering Conference

Geneva, Switzerland (PRWEB) October 24, 2013

Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the Company’s president and CEO, Igor Fish, Ph.D., will present, “Selexis SURE CHO-Mplus™ Libraries: Custom Solutions for Improved Recombinant Protein Production” on Tuesday, November 5 at 4:45 PM at the BIO-Europe 2013 Partnering Conference being held November 4 – 6, at the Messe Wien Exhibition and Congress Center in Vienna, Austria. The Company will be also taking part in the pre-scheduled partnering meetings.

Presentation Abstract:
Stable, high-level production of recombinant proteins requires not only elevated transcription, but also cellular systems that can accommodate all of the protein folding, metabolic, secretory transport and post-translational processing requirements of any given protein. These requirements can vary significantly from protein to protein. Leveraging data from the completed SURE CHO-M Genome and Transciptome, Selexis has engineered the SURE CHO-Mplus libraries to address expression issues such as stalled translocation, improper folding, incomplete post-translational modifications, chromosomal instability or insufficient cellular respiration. With these libraries, Selexis has been able to significantly boost expression over broad range of proteins, including large multimeric structural proteins and and difficult to express proteins.

Companies or individuals attending BIO-Europe can schedule meetings with Selexis (registration required) by visiting:

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

# # #

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Selexis SA Announces Publication in Metabolic Engineering of Data Demonstrating Improvement of Therapeutic Protein Secretion with Engineered CHO Cells
2. Selexis SA to Present and Partner at the BIO-Europe Spring
3. Selexis SA to Partner and Exhibit at BIO 2013
4. Selexis SA Launches SURE CHO-Mplus™ Libraries
5. Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering
6. Advancement in Biologic Protein Expression Webinar Hosted by Selexis SA
7. Selexis SA to Present Data on Improved Selection of Recombinant Protein Production Clones at the Bioprocessing Summit 2013
8. Targeted therapeutics for colon cancer to be presented at AACR meeting
9. NYU Langone experts present research, clinical advances at neurosurgeons meeting
10. Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer
11. Presidential Recognition Awards presented during the 2012 AIUM Annual Convention
Post Your Comments:
(Date:6/26/2016)... ... 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... videos a whole new perspective by using the title layers in ProSlice Levels ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: